Drug intelligence / Profile preview

Respiratory Diseases Vaccine

Development stage: Preclinical
Lead developer: POSVAX
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular, Intranasal

Overview

**Respiratory Diseases Vaccine** is a discovery-stage, virus-like particle vaccine program developed by POSVAX for prevention of respiratory syncytial virus infection and seasonal influenza. The program is intended to generate protective immune responses against respiratory syncytial virus and influenza viruses; individual vaccine antigens, influenza strains, formulation, adjuvant, dosage form, and route of administration have not been publicly specified.

Targets

Flu (Influenza surface proteins)

Beyond the preview

Go deeper on Respiratory Diseases Vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Respiratory Diseases Vaccine.

Explore the full profile